Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Dual Cord Blood Unit (dCBU) Transplantation Increases Short-Term Morbidity, but Has Similar Long-Term Outcome Compared to Matched Unrelated Donor (MUD) Transplantation After Myeloablative Conditioning.

Matt Kalaycio, MD, Brian J. Bolwell, MD, Lisa Rybicki, MS, Edward Copelan, MD, Hien K. Duong, MD, Brian T. Hill, MD, PhD, Robert M. Dean, MD, Brad Pohlman, MD, Steven Andresen, DO, Shawnda Tench, Ronald Sobecks, MD

Blood (2012) 120 (21): 3137.

https://doi.org/10.1182/blood.V120.21.3137.3137

Published: 2012

Journal Articles

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia

Anjali Advani, MD, Paul Elson, Eric D. Hsi, MD, Randall Davis, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Hien K. Duong, MD, Bethany Foster, Mary Lynn Rush, Leslie Farhat, Mikkael A. Sekeres, MD, MS

Blood (2012) 120 (21): 3595.

https://doi.org/10.1182/blood.V120.21.3595.3595

Published: 2012

Journal Articles

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

Blood (2012) 120 (16): 3173–3186.

https://doi.org/10.1182/blood-2012-05-430876

Published: 2012

Includes: Supplemental data

Journal Articles

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Anjali S. Advani, MD, Holly Gundacker, Nolyn Nyatanga, MD, Paul Elson, Peter J. Rosen, MD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Frederick R. Appelbaum, MD

Blood (2011) 118 (21): 2594.

https://doi.org/10.1182/blood.V118.21.2594.2594

Published: 2011

Journal Articles

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Di Sun, Paul Elson, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Marc Earl, PharmD, RPh, Ash A Alizadeh, MD/PhD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Steven E. Coutre, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Anjali S. Advani, MD

Blood (2011) 118 (21): 2552.

https://doi.org/10.1182/blood.V118.21.2552.2552

Published: 2011

Journal Articles

Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.

Anna Brady, MD, Sarah Gibson, MD, Lisa Rybicki, MS, Eric Hsi, MD, Edward Copelan, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Yogen Saunthararajah, MD, Jennifer Bates, Anjali S. Advani, MD

Blood (2010) 116 (21): 1675.

https://doi.org/10.1182/blood.V116.21.1675.1675

Published: 2010

Journal Articles

Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.

Sanjay R. Mohan, MD, Paul Elson, Ramon V. Tiu, MD, Anjali Advani, MD, Yogen Saunthararajah, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Edward Copelan, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 1040.

https://doi.org/10.1182/blood.V116.21.1040.1040

Published: 2010

Journal Articles

Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement

Marc Earl, Pharm., D., R.Ph., Alex Fu, Matt Kalaycio, MD, Anjali Advani, MD, Yogen Saunthararajah, MD, Christina Piks, Barb Tripp, Kristy Grimes, Ronald Sobecks, MD, Edward Copelan, MD, Jaroslaw Maciejewski, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2165.

https://doi.org/10.1182/blood.V116.21.2165.2165

Published: 2010

Journal Articles

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

Sanjay R. Mohan, MD, Alex Fu, Ramon V. Tiu, MD, Edward Copelan, MD, Yogen Saunthararajah, MD, Anjali Advani, MD, Ronald Sobecks, MD, Manual Afable, Ricki Englehaupt, Katarina Paulic, Marc Earl, Pharm., D., R.Ph., Matt Kalaycio, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 4033.

https://doi.org/10.1182/blood.V116.21.4033.4033

Published: 2010

Journal Articles

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Fabiola Traina, MD, PhD, Ania Jankowska, MSC, Hideki Makishima, MD, PhD, Fred H. Hsieh, MD, Yingchun Han, PhD, Christine O'Keefe, PhD, Yuka Sugimoto, MD, PhD, Sanjay R. Mohan, MD, Hadrian Szpurka, PhD, Courtney Prince, Kathryn Guinta, MSC, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Alan E. Lichtin, MD, Anjali S. Advani, MD, Edward Copelan, MD, Ronald Sobecks, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD

Blood (2010) 116 (21): 3076.

https://doi.org/10.1182/blood.V116.21.3076.3076

Published: 2010

Journal Articles

Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics

Mazyar Shadman, MD, MPH, Sarah Gibson, MD, Claudiu Cotta, MD, Yogen Saunthararajah, MD, Eric Hsi, MD, Edward Copelan, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Meagan Effinger, BA, Anjali S. Advani, MD

Blood (2010) 116 (21): 2736.

https://doi.org/10.1182/blood.V116.21.2736.2736

Published: 2010

Journal Articles

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

Vikas Gupta, Martin S. Tallman, Wensheng He, Brent R. Logan, Edward Copelan, Robert Peter Gale, Hanna J. Khoury, Thomas Klumpp, John Koreth, Hillard M. Lazarus, David I. Marks, Rodrigo Martino, David A. Rizzieri, Jacob M. Rowe, Mitchell Sabloff, Edmund K. Waller, John F. DiPersio, Donald W. Bunjes, Daniel J. Weisdorf

Blood (2010) 116 (11): 1839–1848.

https://doi.org/10.1182/blood-2010-04-278317

Published: 2010

Journal Articles

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

David I. Marks, Tao Wang, Waleska S. Pérez, Joseph H. Antin, Edward Copelan, Robert Peter Gale, Biju George, Vikas Gupta, Joerg Halter, H. Jean Khoury, Thomas R. Klumpp, Hillard M. Lazarus, Victor A. Lewis, Philip McCarthy, David A. Rizzieri, Mitchell Sabloff, Jeff Szer, Martin S. Tallman, Daniel J. Weisdorf

Blood (2010) 116 (3): 366–374.

https://doi.org/10.1182/blood-2010-01-264077

Published: 2010

Includes: Supplemental data

Journal Articles

The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).

Mikkael A. Sekeres, MD, MS, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, MD, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, MD, Edward Copelan, MD

Blood (2009) 114 (22): 1043.

https://doi.org/10.1182/blood.V114.22.1043.1043

Published: 2009

Journal Articles

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).

Anna K Brady, BS, BA, Alex Z Fu, PhD, Marc Earl, PharmD, Matt Kalaycio, Anjali Advani, MD, Yogen Saunthararajah, M.D., Ronald Sobecks, Edward Copelan, MD, Mikkael A. Sekeres, MD, MS

Blood (2009) 114 (22): 1012.

https://doi.org/10.1182/blood.V114.22.1012.1012

Published: 2009

Journal Articles

Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies.

Anuj Mahindra, MD, Brian J. Bolwell, Robert Dean, Matt Kalaycio, Belinda Avalos, Lisa Rybicki, Shawnda Tench, Patrick Elder, Ronald Sobecks, John Sweetenham, Brad Pohlman, Steve Andresen, Steve Devine, Edward Copelan

Blood (2009) 114 (22): 2264.

https://doi.org/10.1182/blood.V114.22.2264.2264

Published: 2009

Journal Articles

Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).

Mazyar Shadman, MD, MPH, Sarah Gibson, MD, Claudiu Cotta, MD, PhD, Eric D. Hsi, MD, Edward Copelan, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Yogen Saunthararajah, M.D., Meagan Effinger, B.A., Anjali Advani, MD

Blood (2009) 114 (22): 4681.

https://doi.org/10.1182/blood.V114.22.4681.4681

Published: 2009

Journal Articles

Comparison of Outcomes Between 2-Year Survivors After Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Ronald Sobecks, Robert Dean, Lisa Rybicki, Matt Kalaycio, Brad Pohlman, Steven Andresen, Edward Copelan, Shawnda Tench, Brian J. Bolwell

Blood (2009) 114 (22): 3307.

https://doi.org/10.1182/blood.V114.22.3307.3307

Published: 2009

Journal Articles

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Brian T. Hill, Lisa Rybicki, Brian J. Bolwell, Stephen Smith, Robert Dean, Matt E Kalaycio, MD, Brad Pohlman, Shawnda Tench, Ronald Sobecks, Steven Andresen, Edward Copelan, John William Sweetenham

Blood (2009) 114 (22): 3325.

https://doi.org/10.1182/blood.V114.22.3325.3325

Published: 2009

NARROW

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Dual Cord Blood Unit (dCBU) Transplantation Increases Short-Term Morbidity, but Has Similar Long-Term Outcome Compared to Matched Unrelated Donor (MUD) Transplantation After Myeloablative Conditioning.

A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.

Duration of Antecedent Complete Blood Cell Count (CBC) Abnormalities Predicts Response and Survival Rates In De Novo and Secondary AML.

Outcomes In Acute Myeloid Leukemia (AML) Patients Diagnosed with Myeloid Sarcoma with and without Bone Marrow Involvement

Prior Therapy with DNA Methyltransferase Inhibitors (DNMTI) Predicts for Lower Remission Rates and Worse Survival In Secondary Acute Myeloid Leukemia Patients (sAML) Receiving Remission Induction Therapy

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics

Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).

Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).

Etoposide Priming in Patients with Lymphoma Improves Mobilization without An Increased Risk of Secondary Hematologic Malignancies.

Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).

Comparison of Outcomes Between 2-Year Survivors After Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Non-Relapse Mortality Exceeds Relapse Mortality Six Years After Autologous Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only